Baseline characteristics of all patients included, 2005–2018
| Overall | Male | Female | |
| No of patients | 3856 (100%) | 2060 (53%) | 1796 (47%) |
| Age median (median (IQR)) | 68 (56–78) | 63 (52–74) | 72 (62–81) |
| HCM type: obstructive (%) | 1717 (45) | 789 (38) | 928 (54) |
| Age over 60 (%) | 2610 (68) | 1199 (58) | 1411 (82) |
| Comorbidities | |||
| Hypertension (%) | 1944 (50) | 940 (46) | 1004 (56) |
| IHD (%) | 859 (22) | 490 (24) | 369 (21) |
| AF (%) | 656 (17) | 386 (19) | 270 (15) |
| Heart failure (%) | 523 (14) | 292 (14) | 231 (13) |
| Stroke (%) | 288 (7) | 136 (7) | 152 (9) |
| Chronic obstructive pulmonary disease (%) | 313 (8) | 124 (6) | 189 (11) |
| Chronic kidney disease (%) | 193 (5) | 113 (6) | 80 (5) |
| Concomitant pharmacotherapy | |||
| Beta-blockers (%) | 1413 (37) | 691 (34) | 722 (40) |
| ACE inhibitors (%) | 971 (25) | 556 (27) | 415 (23) |
| Oral anticoagulant therapy (%) | 454 (12) | 271 (13) | 183 (10) |
| Loop diuretics (%) | 847 (22) | 396 (19) | 451 (25) |
| Spironolactone (%) | 293 (8) | 1527 | 141 (8) |
| Angiotensin II inhibitors (%) | 758 (20) | 349 (17) | 402 (22) |
| Calcium channel blockers (%) | 1023 (25) | 469 (23) | 554 (31) |
| Digoxin (%) | 198 (5) | 102 (5) | 96 (5) |
| Amiodarone (%) | 41 (1) | 22 (1) | 19 (1) |
| Implantable cardioverter defibrillator (%) | 62 (2) | 44 (2) | 18 (1) |
AF, atrial fibrillation; HCM, hypertrophic cardiomyopathy; IHD, ischaemic heart disease.